micro-community-banner
 
  • Saved

1yr
Dual roles of extracellular vesicles in acute lymphoblastic leukemia: implications for disease progression and theranostic strategies - PubMed

Dual roles of extracellular vesicles in acute lymphoblastic leukemia: implications for disease progression and theranostic strategies - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39572459/

Acute Lymphoblastic Leukemia (ALL) is a heterogeneous blood cancer characterized by the uncontrolled growth of immature lymphoid cells due to dysregulated signaling pathways. It is the most common pediatric cancer,...

Extracellular vesicles (EVs) in Acute Lymphoblastic Leukemia (ALL) promote tumor progression and resistance while offering potential as biomarkers and therapeutic agents for improved diagnosis and targeted treatments.

  • Saved

1yr
Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies - PubMed

Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38510818/

Despite excellent results in frontline therapy, particularly in pediatric age, refractory Burkitt lymphoma still remains a therapeutic challenge, with dismal outcome. The prognosis is very poor, ranging from less than...

Refractory Burkitt lymphoma has a poor prognosis, with survival rates under 40%. Limited data hinder treatment conclusions, but new targeted drugs and stem cell transplants show potential for improving outcomes.

  • Saved

1yr
American Society of Hematology Annual Meeting 2024

The American Society of Hematology (ASH) is hosting its 66th annual meeting and exposition from Dec. 7 to 10, 2024, in San Diego and online. ASH, the world’s largest professional society of clinicians and scientists dedicated to conquering blood diseases, presents the annual meeting as the most comprehensive hematology event of the year.

Click above to access our conference preview.

  • Saved

1yr
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis - PubMed

Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38238443/

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome driven by pathologic activation of cytotoxic T-lymphocytes and macrophages. Despite advances in diagnostics and management, adult patients with lymphoma-associated HLH (LA-HLH) harbor...

Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) has poor prognosis, with a median survival of 5.1 months. Elevated soluble CD25 levels >10,000 U/ml indicate unfavorable survival, requiring timely diagnosis and lymphoma-specific treatment.

  • Saved

1yr
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies - PubMed

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37907724/

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic approach for the treatment of patients with chemotherapy-refractory or relapsed blood cancers, including acute lymphoblastic leukaemia, diffuse large...

This review discusses resistance mechanisms to CAR-T cell therapies in blood cancers, including CAR-T dysfunction, tumor resistance, and immunosuppressive microenvironment, and highlights strategies to overcome these challenges.